Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Golimumab, a Fully Human Anti-TNFalpha Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis.

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Golimumab, a Fully Human Anti-TNFalpha Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms GO-RAISE
  • Sponsors Centocor

Most Recent Events

  • 01 Dec 2023 Results of post hoc pooled analysis from GO-BEFORE, GO-AFTER, and GO-FORWARD, GO-REVEAL and GO-RAISE assessing Long-term golimumab persistence, published in the Clinical Rheumatology
  • 04 Jun 2022 Results assessing probability of GLM treatment retention over a 5-year period in adult patients with immune-mediated rheumatic diseases, by indication and line of therapy, using pooled data from five Phase III trials (GO-BEFORE, GO-AFTER and GO-FORWARD 3,8 ), PsA (GO-REVEAL), and AS (GO-RAISE)) presented at the 23rd Annual Congress of the European League Against Rheumatism.
  • 05 Jun 2021 Results assessing effect of GLM on HRQoL, back pain, and sleep disturbances in phase-3 studies (NCT00265083 - GO RAISE and NCT01248793) in Asian patients with ankylosing spondylitis, presented at the 22nd Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top